3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
24
Recruiting
9
Unknown
8
Terminated
2
Not yet recruiting
2
No longer available
1
Enrolling by invitation
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
74
Breast
33
Head & Neck
9
Thoracic
4
Endocrine
3
Genitourinary
2
Tumor-Agnostic
1
Other solid neoplasm
1
NET
1
Gynecologic
1
Dermatologic
1
Conditions
Childhood Solid Tumor
1
Interventions
pembrolizumab
27
Nivolumab
11
Pemetrexed
10
Cyclophosphamide
10
Carboplatin
10
atezolizumab
9
Specimen Handling
8
Cisplatin
8
Ipilimumab
6
Biopsy
6
Injections
5
tislelizumab
4
spartalizumab
4
fludarabine
4
Vincristine
4
Radiotherapy
4
Proton Therapy
4
Platinum
4
Paclitaxel
4
Drug Therapy
4
Docetaxel
4
Bevacizumab
4
1,2-diaminocyclohexaneplatinum II citrate
4
durvalumab
3
Trastuzumab
3
Etoposide
3
Cetuximab
3
zimberelimab
2
trametinib
2
tocilizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Capecitabine
×
Other solid neoplasm
×
Clear all
NCT03585465
2026-03-18
Metro-PD1
Centre Oscar Lambret
Phase 1/2
Active not recruiting
63 enrolled